{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-010652","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.469672+00:00","generated_at":"2026-06-17T06:58:39.050140+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"RenovoRx raises $5M in registered direct offering and private placement of common stock and warrants","bullets":["Gross proceeds of ~$5M from sale of 1,557,632 shares (or pre-funded warrants) at $3.21 per share.","Concurrent private placement of warrants to purchase 1,947,040 shares at $3.21, exercisable for 5.5 years.","Offering priced at-the-market under Nasdaq rules; closing on April 3, 2023.","Roth Capital Partners acted as exclusive placement agent; net proceeds for working capital and general corporate purposes.","Pre-funded warrants priced at $3.2099 each to avoid investor exceeding 4.99% beneficial ownership."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-010652","json":"https://secwatch.observer/filing/0001493152-23-010652.json","markdown":"https://secwatch.observer/filing/0001493152-23-010652.md","text":"https://secwatch.observer/filing/0001493152-23-010652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223010652/0001493152-23-010652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223010652/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:58:39.050140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"64318b65f9bc5ce72d2fde059e4ce4ce06e8ac8f","claim":"RenovoRx, Inc. entered into Securities Purchase Agreement with a certain institutional investor valued at approximately $5.00 million (effective 2023-03-30).","evidence_excerpt":"On March 30, 2023, RenovoRx, Inc. (the “ Company ,” “ we ” or “ us ”) entered into a securities purchase agreement (“ Securities Purchase Agreement ”) with a certain institutional investor (“ Purchaser ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223010652/0001493152-23-010652-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a certain institutional investor"},{"label":"Value","value":"approximately $5.00 million"},{"label":"Effective","value":"2023-03-30"}],"fact_type":"material_agreement"},{"claim_id":"84c55568f57d81920bc2244864240d4db4371f70","claim":"RenovoRx, Inc. entered into Placement Agreement with Roth Capital Partners, LLC (effective 2023-03-30).","evidence_excerpt":"Roth Capital Partners, LLC (the “ Placement Agent ”) acted as the exclusive placement agent for the Offerings, pursuant to a placement agency agreement (the “ Placement Agreement ”), dated March 30, 2023, by and between the Company and the Placement Agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223010652/0001493152-23-010652-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Roth Capital Partners, LLC"},{"label":"Effective","value":"2023-03-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}